Prof. Paul-Henri Lambert, MD
Prof. Paul-Henri Lambert, MD, is now associated with the Centre of Vaccinology in the Department of Pathology and Immunology at University of Geneva. He is directing the International Advanced Course of Vaccinology (ADVAC) organized under the auspices of the Fondation Mérieux and University of Geneva. He is a member of the Governing Board of the Tuberculosis Vaccine Initiative (TBVI), past-chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS) and of the Global Advisory Committee on Vaccine Safety of the World Health Organization (WHO). In 1987, he was appointed as chief of Microbiology and Immunology at the World Health Organization and in 1994, chief of the Vaccine Research and Development, WHO Global Program for Vaccines and Immunization. During this time he was deeply involved in co-ordination of research aiming at the development of vaccines against diseases of major importance in developing countries.
Dr. Martin L. Moore
Dr. Moore is an Assistant Professor at Emory University, Director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV), and a Children’s Healthcare of Atlanta Research Scholar. He is a recognized leader in RSV research and has been running an NIH-funded laboratory in the Department of Pediatrics at Emory since 2008. Dr. Moore’s work on RSV vaccines was recognized as Emory University’s Innovation of the year in 2013. Dr. Moore is co-inventor of numerous RSV-related technologies and is a frequent national/international lecturer on RSV.
Dr. Urs Regenass
Dr. Urs Regenass has over 30 years experience in pharmaceutical drug discovery, most recently as Senior Director Oncology at Actelion Pharmaceuticals. Before, he led the oncology biology unit at Ciba then, first at Ciba and then Novartis he became a member of the global research management board and led the global Core Technology department in research. From Novartis, he joined Discovery Partners International, a CRO headquartered in San Diego as VP Drug Discovery and as CEO of the Allschwil, Switzerland site. Since 2016 he provides his knowledge in drug discovery and oncology as an independent consultant. Urs has published over 50 articles and book chapters in the field of oncology and drug discovery. He served on the board of directors of 2 start-up companies and lectured for 7 years at the university of Basel in experimental oncology. Urs obtained his PhD in Cell Biology at the Biocenter, University of Basel.
Prof. Gerd Pluschke
Prof. Pluschke is Head of the Molecular Immunology Unit and the Department of Medical Parasitology and Infection Biology at the Swiss Tropical and Public Health Institute (Swiss TPH). Prior to joining the Institute, he worked as a scientist at the Max-Planck-Institute for Molecular Genetics, the Basel Institute for Immunology and for Ciba Pharma Research. Prof. Pluschke has published more than 150 papers and holds several patents. He graduated in Biochemistry, receiving his Doctorate from the University of Tubingen.
Prof. Richard Ulevitch
Prof. Ulevitch is Venture Partner at 5AM Ventures (Menlo Park CA USA), Professor of Immunology and Chairman Emeritus at The Scripps Research Institute ( La Jolla, CA USA). For nearly four decades, Prof. Ulevitch has performed research to understand the role of the immune system in human disease. He also serves as a scientific advisor to Aravis Ventures and was previously an advisor to the Lombard Odier Immunology Fund. Prof. Ulevitch currently serves on the Scientific Advisory Boards of multiple biotechnology companies. He has authored more than 200 scientific publications and is a co-inventor on multiple patents. He received an A.B. from Washington and Jefferson College and a Ph.D. in Biochemistry from the University of Pennsylvania and joined The Scripps Research Institute in 1972.
Dr. Rinaldo Zurbriggen
Rinaldo Zurbriggen is currently Director, Strategic Growth Investments and Head Microbial Program Management at Lonza Visp. Previously he was Head of Viral Research at Berna Biotech and later on co-founder and Chief Scientific Officer of Pevion Biotech. He has been working in the pharmaceutical and vaccine field for more than 15 years and has brought three vaccine candidates from preclinical testing to human clinical trials. Dr. Zurbriggen has published more than 50 peer-reviewed papers in scientific journals and is author of chapters in three different scientific books. He graduated from the University of Fribourg with a Doctorate in Biochemistry.
Dr. Urs Breitenstein
Dr. Breitenstein is one of the leading valuation experts in Switzerland. He is Partner at Hoffmann & Co. Prior to Hoffmann & Co fe worked as equity analyst for a Swiss Bank, then for PricewaterhouseCoopers and, most recently, for Deloitte in Zurich, where he was a partner and team leader of the M&A- as well as of the internal life science industry team. He holds a Doctorate in economics from the University of Basel.